Om Indlægget
The lecture gives an overview of antiresorptive medication and describes current knowledge and published data of dental implants in patients on antiresorptives.
The lecture is based on two ongoing cohort studies. One feasibility study (REHAB-study) with the purpose of examining the outcome of dental implant insertion in patients on high-dose antiresorptive treatment (HDAR) and evaluating their quality of life after dental rehabilitation. Three groups of patients with bone metastases on HDAR are included: (i) those with a previous tooth extraction, who did not develop medication-related osteonecrosis of the jaws (MRONJ); (ii) those who developed MRONJ and were successfully surgically treated and cured for at least 3 months and finally (iii) patients, who had ongoing MRONJ and planned for surgical resection with implants placed simultaneously. To date (25.2.2020), 21 patients are included and a total of 36 implants are inserted. HDAR include bisphosphonates (17/21), denosumab (4/21). The second study is a randomized controlled study evaluating the effect of HDAR drug holiday. Preliminary results from both studies will be presented and discussed.
Speaker
Tandlæge Camilla Ottesen ph.d.-stud.
Camilla Ottesen is a PhD student at the department of Oral Rehabilitation, University of Copenhagen and the department of Oral & Maxillofacial Surgery, Copenhagen University Hospital.
Camilla Ottesen has conducted research in the field of medication-related osteonecrosis of the jaw (MRONJ) since 2014. She was a research-year student in 2014-2015 and graduated from the University of Copenhagen in 2016 – since she has worked as a private practice dentist. In February 2018, she started her PhD entitled “Influence of antiresorptive drug holiday in cancer patients needing tooth extraction and oral rehabilitation of these patients”.
